Element Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

Element Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-7,017	Closed	-$995K	–	76
2025 Q4	$995K	Buy	+7,017	New	+$1.02M	0.48%	51
2018 Q4	–	Sell	-30,619	Closed	-$3.77M	–	804
2018 Q3	$3.77M	Buy	30,619 +23,836	+351%	+$2.7M	0.08%	208
2018 Q2	$666K	Buy	+6,783	New	+$607K	0.02%	312

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Element Capital Management's NBIX Position: Q1 2026 in Review

Element Capital Management sold out of Neurocrine Biosciences (NBIX) in Q1 2026, closing a stake of 7,017 shares — an estimated $995K sold.

Element Capital Management first reported a position in NBIX in Q2 2018 and held it in 3 quarters. The position peaked at $3.77M in Q3 2018. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

Element Capital Management reported no remaining Neurocrine Biosciences position as of Q1 2026 after selling out during the quarter.
Element Capital Management sold 7,017 Neurocrine Biosciences shares in Q1 2026, an estimated $995K.
Element Capital Management first reported a position in Neurocrine Biosciences in Q2 2018 and held it in 3 quarters.
Element Capital Management's Neurocrine Biosciences position peaked at $3.77M in Q3 2018.
694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Element Capital Management's 13F filing for Q1 2026, filed 12 May 2026.